Remote Monitoring & Telemedicine for Leukemia Care
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether technology can improve care for leukemia patients after bone marrow transplants (BMT) or CAR-T therapy. It focuses on using gadgets and telemedicine to manage care at home, aiming for better coordination and timely treatment referrals. Participants will use a wearable device (BioIntelliSense BioButton Rechargeable) and a communication platform (Memora Health two-way patient engagement platform) to stay in touch with their healthcare team. Individuals who have had BMT or CAR-T therapy, live in the Denver area, and have reliable internet and caregiver support at home might be suitable candidates. As an unphased trial, this study offers the chance to explore innovative care solutions that could enhance the post-treatment experience.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What prior data suggests that this technology-assisted in-home oncology care program is safe for leukemia patients?
Research has shown that the BioIntelliSense BioButton, a wearable device for remote monitoring, effectively tracks vital signs and detects early health issues. This medical-grade device meets high safety standards. Previous studies found it effective in hospitals, with no major safety problems reported.
Studies suggest that the Memora Health two-way patient engagement platform improves patient interaction through text messages, helping patients stay involved in their care. These studies have not linked its use to any major safety concerns.
The technology-assisted in-home oncology care program aims to enhance home care for patients. Research indicates that this program can improve care coordination and management without introducing new safety risks. Overall, past studies consider these tools and programs safe and well-tolerated.12345Why are researchers excited about this trial?
Researchers are excited about using remote monitoring and telemedicine for leukemia care because it offers a unique approach to post-treatment recovery. Unlike traditional care options that require frequent in-person visits, this method leverages technology to monitor patients' health at home, using devices like the BioIntelliSense BioButton and a two-way patient engagement platform. This not only provides continuous health tracking but also enhances patient convenience and reduces the need for hospital trips, potentially leading to quicker interventions and improved outcomes. By personalizing care through real-time data and communication, this approach aims to make leukemia treatment more efficient and patient-centered.
What evidence suggests that this technology-assisted in-home oncology care program is effective for leukemia care?
In this trial, participants will use remote monitoring tools like the BioIntelliSense BioButton to track vital signs and detect early health issues. Research has shown that this wearable device provides crucial information on key health indicators, especially for patients after treatments like bone marrow transplants or CAR-T therapy. Additionally, participants will engage with the Memora Health platform, which connects patients with their care team through text messages, enhancing communication and ensuring timely care. Overall, the technology-assisted home care program under study has shown promise in improving care coordination and patient outcomes by allowing patients to recover at home while being closely monitored.12345
Who Is on the Research Team?
Glen Peterson
Principal Investigator
University of Colorado, Denver
Are You a Good Fit for This Trial?
This trial is for adults aged 18-89 with leukemia who are stable enough to be discharged home after a bone marrow transplant or CAR-T therapy. They must have caregiver support, reliable phone and internet service, live within 45 minutes of the AMC in Denver, and agree to use technology for remote care.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive technology-assisted in-home oncology care, including remote patient monitoring, telemedicine, and home-based health care services
Follow-up
Participants are monitored for safety and effectiveness after treatment, focusing on symptoms like febrile neutropenia, infection, cytokine release syndrome, and neurotoxicity
What Are the Treatments Tested in This Trial?
Interventions
- BioIntelliSense BioButton Rechargable
- Memora Health two-way patient engagement platform provided by RC
- Technology-assisted in-home oncology care program
Trial Overview
The study tests an at-home oncology care program using BioIntelliSense BioButton and Memora Health platform for patients post-BMT or CAR-T. It includes remote monitoring, telemedicine, and home health services to improve care coordination.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will be recruited for this study from among three discrete patient populations: * Allogeneic BMT patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the Anschutz Medical Campus (AMC) for at least 90 days post-transplant. * Autologous BMT patients receiving care at UCHealth who are planning to reside in the Denver metro Area within 45 minutes of the AMC for at least 30 days post-transplant. * CAR-T patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the AMC for at least 30 days post treatment.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
Reimagine Care
Collaborator
Citations
Using technology for patient-centered care at home after ...
Among patients who receive CAR T-cell therapy, between 37% and 93% experience some degree of CRS and between 20% and 60% experience ICANS, with ...
NCT05826288 | Oncology Care at Home for BMT and CAR-T
This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data ...
Oncology Care at Home for BMT and CAR-T
Description: This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for ...
BioButton®* Multi-Parameter Wearable
The BioButton®* medical-grade wearable provides trending data on key vital signs and biometrics that serve as early indicators of patient decline.
(PDF) A Retrospective Observational Study of Continuous ...
One such device is the BioButton ® system (BioIntelliSense, Golden, CO, USA) which demonstrated promising results in a 2024 retrospective study ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.